The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel

Telomeres are repetitive (TTAGGG)n DNA sequences found at the end of chromosomes that protect the ends from recombination, end to end fusions, and recognition as damaged DNA. Telomerase activity can be detected in 85% to 90% of human tumors, which stabilizes telomeres to prevent apoptosis or cellular senescence. Previous reports showed the efficacy of the novel telomerase template antagonist, GRN163L, as a potential anticancer agent. The objective of the present study was to elucidate the molecular effects of GRN163L in MDA-MB-231 breast cancer cells and to determine whether GRN163L could be used in mechanism-based combination therapy for breast cancer. We observed that GRN163L reduced MDA-MB-231 growth rates without a significant effect on breast cancer cell viability within the first 14 days in vitro. In addition, GRN163L altered cell morphology, actin filament organization, and focal adhesion formation in MDA-MB-231 cells. Importantly, the cellular response to GRN163L significantly augmented the effects of the microtubule stabilizer paclitaxel in MDA-MB-231 breast cancer cell growth in vitro and in vivo compared with paclitaxel alone or a mismatch control oligonucleotide plus paclitaxel. Furthermore, in vitro MDA-MB-231 invasive potential was significantly inhibited with GRN163L and paclitaxel. These data support a rationale for potentially combining GRN163L with paclitaxel for the treatment of breast cancer in the clinical setting. [Mol Cancer Ther 2009;8(7):2027–35]

[1]  V. Fedele,et al.  Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of β‐tubulins , 2007 .

[2]  J. Au,et al.  Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach. , 2003, Cancer research.

[3]  Guido Kroemer,et al.  Cell death by mitotic catastrophe: a molecular definition , 2004, Oncogene.

[4]  J. Guan,et al.  Focal adhesion kinase in integrin-mediated signaling. , 1999, Frontiers in bioscience : a journal and virtual library.

[5]  D. Ribnikar,et al.  Metastatic breast cancer. , 2014, Current opinion in oncology.

[6]  J. Shay,et al.  Telomerase: a target for cancer therapeutics. , 2002, Cancer cell.

[7]  E. Rowinsky.  The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. , 1997, Annual review of medicine.

[8]  D. Schlaepfer,et al.  Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration. , 1999, Journal of cell science.

[9]  G. Sledge,et al.  Telomerase Template Antagonist GRN163L Disrupts Telomere Maintenance, Tumor Growth, and Metastasis of Breast Cancer , 2006, Clinical Cancer Research.

[10]  T. Fojo,et al.  Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  M. Robinson,et al.  Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. , 1999, Genes & development.

[12]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[13]  J. Shay,et al.  Nonradioactive detection of telomerase activity using the telomeric repeat amplification protocol , 2006, Nature Protocols.

[14]  C. Autexier,et al.  Pharmacological Telomerase Inhibition Can Sensitize Drug-Resistant and Drug-Sensitive Cells to Chemotherapeutic Treatment , 2005, Molecular Pharmacology.

[15]  G. Mills,et al.  An Inherent Role of Integrin-Linked Kinase-Estrogen Receptor α Interaction in Cell Migration , 2006 .

[16]  B. Herbert,et al.  Specific telomere dysfunction induced by GRN163L increases radiation sensitivity in breast cancer cells. , 2007, International journal of radiation oncology, biology, physics.

[17]  J. Shay,et al.  Antiadhesive effects of GRN163L--an oligonucleotide N3'->P5' thio-phosphoramidate targeting telomerase. , 2007, Cancer research.

[18]  J. Shay,et al.  Telomerase and differentiation in multicellular organisms: turn it off, turn it on, and turn it off again. , 2002, Differentiation; research in biological diversity.

[19]  C. Beaudry,et al.  Differential role of proline-rich tyrosine kinase 2 and focal adhesion kinase in determining glioblastoma migration and proliferation. , 2003, Molecular cancer research : MCR.

[20]  M. Manns,et al.  Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma , 2005, Hepatology.

[21]  S. Barni,et al.  Chemotherapy for metastatic breast cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  T. H. Wang,et al.  Paclitaxel‐induced cell death , 2000, Cancer.

[23]  M. Cammer,et al.  Estrogen and resveratrol regulate Rac and Cdc42 signaling to the actin cytoskeleton of metastatic breast cancer cells. , 2007, Neoplasia.

[24]  J. Shay,et al.  Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer , 2006, Breast Cancer Research and Treatment.

[25]  M. Wirth,et al.  Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  Mi Ae Kim,et al.  Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype , 2005, Oncogene.

[27]  C. Harley,et al.  Lipid modification of GRN163, an N3′ → P5′ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition , 2005, Oncogene.

[28]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[29]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.

[30]  W. Hahn,et al.  Inhibition of telomerase limits the growth of human cancer cells , 1999, Nature Medicine.

[31]  J. Shay.  Telomerase therapeutics: telomeres recognized as a DNA damage signal: commentary re: K. Kraemer et al., antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin. Cancer Res., 9: 3794-3800, 2003. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  W. B. Derry,et al.  Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. , 1996, Cancer research.

[33]  J. Parsons,et al.  Focal adhesion kinase: the first ten years , 2003, Journal of Cell Science.

[34]  J. Shay,et al.  Telomerase activity in human germline and embryonic tissues and cells. , 1996, Developmental genetics.

[35]  I. Gelman.  Pyk 2 FAKs, any two FAKs , 2003, Cell biology international.

[36]  M. Cerone,et al.  Telomerase inhibition enhances the response to anticancer drug treatment in human breast cancer cells , 2006, Molecular Cancer Therapeutics.

[37]  J. Zhao,et al.  Pyk2 and FAK differentially regulate progression of the cell cycle. , 2000, Journal of Cell Science.

[38]  G. Mills,et al.  Telomere 3′ overhang‐specific DNA oligonucleotides induce autophagy in malignant glioma cells , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  D. Corey,et al.  Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[40]  C. Damsky,et al.  FAK integrates growth-factor and integrin signals to promote cell migration , 2000, Nature Cell Biology.

[41]  S. Lockett,et al.  Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. , 2008, Cancer research.